Skymap Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
as on 29-06-2024
- Paid Up Capital ₹ 5.00 M
as on 29-06-2024
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 721.44 Cr
as on 29-06-2024
- Satisfied Charges ₹ 8.00 Cr
as on 29-06-2024
- Revenue 14.54%
(FY 2023)
- Profit -95.39%
(FY 2023)
- Ebitda -18.64%
(FY 2023)
- Net Worth -34.19%
(FY 2023)
- Total Assets -16.72%
(FY 2023)
About Skymap Pharmaceuticals
The Corporate was formerly known as Skymap Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹721.44 Cr. The company has closed loans amounting to ₹8.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vinod Gupta, Manish Garg, and Sanjay Gupta serve as directors at the Company.
- CIN/LLPIN
U24233DL2006PTC150088
- Company No.
150088
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Skymap Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Garg  | Director | 29-Sep-2015 | Current |
| Vinod Gupta | Director | 12-Oct-2017 | Current |
| Sanjay Gupta | Director | 24-Jun-2006 | Current |
Financial Performance and Corporate Structure Insights of Skymap Pharmaceuticals.
Skymap Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.54% increase. The company also saw a substantial fall in profitability, with a 95.39% decrease in profit. The company's net worth observed a substantial decline by a decrease of 34.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skymap Pharmaceuticals?
In 2022, Skymap Pharmaceuticals had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Glensmith Labs Private LimitedActive 10 years 1 monthManish Garg and Sanjay Gupta are mutual person
Datt Infrastructure And Services Private LimitedActive 29 years 9 monthsVinod Gupta and Sanjay Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 25 Mar 2020 | ₹9.50 M | Open |
Hdfc Bank Limited Creation Date: 02 Aug 2018 | ₹284.84 Cr | Open |
Hdfc Bank Limited Creation Date: 26 May 2017 | ₹284.84 Cr | Open |
How Many Employees Work at Skymap Pharmaceuticals?
Skymap Pharmaceuticals has a workforce of 314 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skymap Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skymap Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
